Botuo Biotech released its 2026 interim report. In the first half of the year, the company's operating revenue was 215 million yuan, up 5.6% year on year, but it posted a loss of 16.55 million yuan, down 233.5% year on year. Second-quarter operating revenue was 125 million yuan, up 8.6% year on year, while net profit attributable to the parent company was a loss of 6.34 million yuan, down 272.9% year on year. The company said the decline in net profit was mainly due to a significant increase in research and development expenses caused by greater investment in new product development, as well as exchange losses from the depreciation of the US dollar. As of the end of the second quarter, the company's total assets were 2.405 billion yuan, down 5.3% from the end of the previous year, and net assets attributable to the parent company were 2.141 billion yuan, down 9.7% from the end of the previous year. The company's main business, core competitiveness, and ability to continue as a going concern have not undergone major changes. During the reporting period, it launched multiple new drug testing and infectious disease testing products, and has obtained a total of 1,014 international certifications, including 848 European Union CE certificates.
Hangzhou Biotest Biotech Co LtdFirst-half loss of 16.55 million yuan, down 233.5% year on year, due to higher R&D expenses and exchange losses.
